IPP Bureau
Roche’s Gazyva shows breakthrough results in Lupus phase III trial
By IPP Bureau - March 07, 2026
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
FDA nod to groundbreaking combo therapy for relapsed multiple myeloma
By IPP Bureau - March 07, 2026
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
Roche’s experimental obesity drug shows strong weight-loss results in mid-stage trial
By IPP Bureau - March 07, 2026
The company announced positive topline data from the Phase II ZUPREME-1 trial
Evogene narrows focus to AI-driven molecule discovery after major strategic overhaul
By IPP Bureau - March 07, 2026
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026
By IPP Bureau - March 07, 2026
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Lonza to set up Global Capability Centre in Hyderabad
By IPP Bureau - March 06, 2026
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Merck delivers resilient 2025 performance despite global headwinds
By IPP Bureau - March 06, 2026
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
CordenPharma expands boulder presence with 64,000-Sq-Ft Lease at BioMed Realty’s Flatiron Park
By IPP Bureau - March 06, 2026
The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant
argenx reports breakthrough Phase 3 results for VYVGART in ocular myasthenia gravis
By IPP Bureau - March 06, 2026
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
Sea Urchin spines inspire breakthrough sensor that detects water flow instantly
By IPP Bureau - March 06, 2026
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
FUJIFILM Biotechnologies launches purification technology for biologics
By IPP Bureau - March 06, 2026
ShunzymeX leverages a proprietary protease to streamline purification
Bayer expands MRXperion power injector capabilities with FDA nod
By IPP Bureau - March 06, 2026
The system also introduces Imaging Scanner Interface 2 (ISI2) capability, enabling direct communication between injector and scanner to improve exam coordination and operational efficiency
FDA okays JUXTAPID for kids with ultra-rare genetic cholesterol disorder
By IPP Bureau - March 06, 2026
Philips unveils next-gen CT system ‘Rembra’
By IPP Bureau - March 06, 2026
Designed for intense clinical environments, Rembra can handle up to 270 exams per day
Alembic enters US branded market with first sales of Pivya UTI treatment
By IPP Bureau - March 06, 2026
Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC
